Free Trial
→ Bank of America: 'Digital Dollar Inevitable' (From Decentralized Masters) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
DexCom, Inc. stock logo
DXCM
DexCom
$84.24
+2.4%		$85.82
$54.11
▼
$92.59
$31.38B1.455.02 million shs1.51 million shs
GE HealthCare Technologies Inc. stock logo
GEHC
GE HealthCare Technologies
$79.86
+4.3%		$68.45
$58.75
▼
$89.77
$36.10B0.644.23 million shs1.83 million shs
Insulet Corporation stock logo
PODD
Insulet
$152.26
+1.7%		$140.91
$126.40
▼
$354.88
$10.57B1.061.39 million shs555,946 shs
ResMed Inc. stock logo
RMD
ResMed
$231.44
+0.7%		$231.87
$180.26
▼
$277.67
$32.55B0.771.30 million shs596,728 shs
10 Best Stocks to Own in Fall 2026 Cover
10 Best Stocks to Own in Fall 2026

AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
DexCom, Inc. stock logo
DXCM
DexCom
0.00%+5.58%-3.60%-5.75%+41.34%
GE HealthCare Technologies Inc. stock logo
GEHC
GE HealthCare Technologies
0.00%+7.17%+19.10%+9.81%+2.16%
Insulet Corporation stock logo
PODD
Insulet
0.00%+0.45%+13.66%-11.80%-52.18%
ResMed Inc. stock logo
RMD
ResMed
0.00%-8.71%+5.42%+7.27%-6.45%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
DexCom, Inc. stock logo
DXCM
DexCom
$84.24
+2.4%		$85.82
$54.11
▼
$92.59
$31.38B1.455.02 million shs1.51 million shs
GE HealthCare Technologies Inc. stock logo
GEHC
GE HealthCare Technologies
$79.86
+4.3%		$68.45
$58.75
▼
$89.77
$36.10B0.644.23 million shs1.83 million shs
Insulet Corporation stock logo
PODD
Insulet
$152.26
+1.7%		$140.91
$126.40
▼
$354.88
$10.57B1.061.39 million shs555,946 shs
ResMed Inc. stock logo
RMD
ResMed
$231.44
+0.7%		$231.87
$180.26
▼
$277.67
$32.55B0.771.30 million shs596,728 shs
10 Best Stocks to Own in Fall 2026 Cover
10 Best Stocks to Own in Fall 2026

AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
DexCom, Inc. stock logo
DXCM
DexCom
0.00%+5.58%-3.60%-5.75%+41.34%
GE HealthCare Technologies Inc. stock logo
GEHC
GE HealthCare Technologies
0.00%+7.17%+19.10%+9.81%+2.16%
Insulet Corporation stock logo
PODD
Insulet
0.00%+0.45%+13.66%-11.80%-52.18%
ResMed Inc. stock logo
RMD
ResMed
0.00%-8.71%+5.42%+7.27%-6.45%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
DexCom, Inc. stock logo
DXCM
DexCom
3.00
Buy$92.9112.91% Upside
GE HealthCare Technologies Inc. stock logo
GEHC
GE HealthCare Technologies
2.52
Moderate Buy$80.575.22% Upside
Insulet Corporation stock logo
PODD
Insulet
2.46
Hold$186.6824.72% Upside
ResMed Inc. stock logo
RMD
ResMed
2.41
Hold$253.699.94% Upside

Current Analyst Ratings Breakdown

Latest PODD, RMD, GEHC, and DXCM Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/30/2026
ResMed Inc. stock logo
RMD
ResMed
Needham & Company LLC logo
Needham & Company LLC
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingHold
10/30/2026
ResMed Inc. stock logo
RMD
ResMed
Mizuho logo
Mizuho
Subscribe to MarketBeat All Access to unlock brokerage rankings
Set Price Target$270.00
10/30/2026
DexCom, Inc. stock logo
DXCM
DexCom
Raymond James Financial, Inc. logo
Raymond James Financial
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingStrong-Buy$97.00
10/30/2026
DexCom, Inc. stock logo
DXCM
DexCom
JPMorgan Chase & Co. logo
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access to unlock brokerage rankings
Boost Price TargetNeutral$82.00 ➝ $85.00
10/30/2026
DexCom, Inc. stock logo
DXCM
DexCom
Barclays PLC logo
Barclays
Subscribe to MarketBeat All Access to unlock brokerage rankings
Boost Price TargetOverweight$115.00 ➝ $120.00
10/30/2026
ResMed Inc. stock logo
RMD
ResMed
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access to unlock brokerage rankings
Boost Price TargetNeutral$240.00 ➝ $270.00
10/30/2026
ResMed Inc. stock logo
RMD
ResMed
Wells Fargo & Company logo
Wells Fargo & Company
Subscribe to MarketBeat All Access to unlock brokerage rankings
Boost Price TargetEqual Weight$215.00 ➝ $250.00
10/30/2026
ResMed Inc. stock logo
RMD
ResMed
Royal Bank Of Canada logo
Royal Bank Of Canada
Subscribe to MarketBeat All Access to unlock brokerage rankings
Boost Price TargetOutperform$262.00 ➝ $288.00
10/30/2026
ResMed Inc. stock logo
RMD
ResMed
KeyCorp logo
KeyCorp
Subscribe to MarketBeat All Access to unlock brokerage rankings
Boost Price TargetOverweight$267.00 ➝ $277.00
10/29/2026
GE HealthCare Technologies Inc. stock logo
GEHC
GE HealthCare Technologies
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access to unlock brokerage rankings
Boost Price TargetNeutral$71.00 ➝ $79.00
10/29/2026
GE HealthCare Technologies Inc. stock logo
GEHC
GE HealthCare Technologies
Barclays PLC logo
Barclays
Subscribe to MarketBeat All Access to unlock brokerage rankings
Boost Price TargetOverweight$85.00 ➝ $95.00
(Data available from 11/2/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
DexCom, Inc. stock logo
DXCM
DexCom
$4.66B6.58$2.77 per share29.72$7.04 per share11.69
GE HealthCare Technologies Inc. stock logo
GEHC
GE HealthCare Technologies
$20.63B1.68$5.88 per share13.03$22.80 per share3.36
Insulet Corporation stock logo
PODD
Insulet
$2.71B3.83$6.32 per share23.67$21.54 per share6.95
ResMed Inc. stock logo
RMD
ResMed
$5.65B5.74$12.98 per share17.78$45.40 per share5.08
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
DexCom, Inc. stock logo
DXCM
DexCom
$836.30M$2.5532.2726.461.3719.42%37.77%15.98%N/A
GE HealthCare Technologies Inc. stock logo
GEHC
GE HealthCare Technologies
$2.08B$4.7416.1514.081.939.96%20.45%5.97%N/A
Insulet Corporation stock logo
PODD
Insulet
$247.10M$5.3527.9819.411.1812.29%29.29%13.31%11/4/2026 (Confirmed)
ResMed Inc. stock logo
RMD
ResMed
$1.52B$10.9821.0217.501.4127.79%26.42%19.43%N/A

Latest PODD, RMD, GEHC, and DXCM Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/4/2026Q3 2026
Insulet Corporation stock logo
PODD
Insulet
$1.59N/AN/AN/A$832.63 millionN/A
10/29/2026Q3 2026
DexCom, Inc. stock logo
DXCM
DexCom
$0.6750$0.73+$0.0550$0.72$1.33 billion$1.34 billion
10/29/2026Q1 2027
ResMed Inc. stock logo
RMD
ResMed
$2.67$2.91+$0.24$2.92$1.39 billion$1.41 billion
10/28/2026Q3 2026
GE HealthCare Technologies Inc. stock logo
GEHC
GE HealthCare Technologies
$1.20$1.34+$0.14$1.36$5.35 billion$5.51 billion
8/6/2026Q4 2026
ResMed Inc. stock logo
RMD
ResMed
$2.89$2.95+$0.06$2.64$1.46 billion$1.46 billion
8/5/2026Q2 2026
Insulet Corporation stock logo
PODD
Insulet
$1.47$1.66+$0.19$1.37$787.39 million$801.70 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
DexCom, Inc. stock logo
DXCM
DexCom
N/AN/AN/AN/AN/A
GE HealthCare Technologies Inc. stock logo
GEHC
GE HealthCare Technologies
$0.160.21%N/A3.38%1 Years
Insulet Corporation stock logo
PODD
Insulet
N/AN/AN/AN/AN/A
ResMed Inc. stock logo
RMD
ResMed
$2.641.14%+9.00%24.04%13 Years

Latest PODD, RMD, GEHC, and DXCM Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
10/29/2026
ResMed Inc. stock logo
RMD
ResMed
quarterly$0.661.05%11/12/202611/12/202612/17/2026
9/22/2026
GE HealthCare Technologies Inc. stock logo
GEHC
GE HealthCare Technologies
quarterly$0.040.22%10/23/202610/23/202611/13/2026
8/6/2026
ResMed Inc. stock logo
RMD
ResMed
quarterly$0.661.15%8/20/20268/20/20269/24/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
DexCom, Inc. stock logo
DXCM
DexCom
0.49
1.74
1.40
GE HealthCare Technologies Inc. stock logo
GEHC
GE HealthCare Technologies
0.86
1.30
1.01
Insulet Corporation stock logo
PODD
Insulet
0.65
2.48
1.83
ResMed Inc. stock logo
RMD
ResMed
0.04
2.65
1.88

Institutional Ownership

CompanyInstitutional Ownership
DexCom, Inc. stock logo
DXCM
DexCom
97.75%
GE HealthCare Technologies Inc. stock logo
GEHC
GE HealthCare Technologies
82.06%
Insulet Corporation stock logo
PODD
Insulet
N/A
ResMed Inc. stock logo
RMD
ResMed
54.98%

Insider Ownership

CompanyInsider Ownership
DexCom, Inc. stock logo
DXCM
DexCom
0.28%
GE HealthCare Technologies Inc. stock logo
GEHC
GE HealthCare Technologies
0.36%
Insulet Corporation stock logo
PODD
Insulet
0.36%
ResMed Inc. stock logo
RMD
ResMed
0.58%
CompanyEmployeesShares OutstandingFree FloatOptionable
DexCom, Inc. stock logo
DXCM
DexCom
11,000372.95 million371.91 millionOptionable
GE HealthCare Technologies Inc. stock logo
GEHC
GE HealthCare Technologies
54,000452.14 million450.51 millionOptionable
Insulet Corporation stock logo
PODD
Insulet
5,40069.35 million69.10 millionOptionable
ResMed Inc. stock logo
RMD
ResMed
11,370140.64 million139.82 millionOptionable

Recent News About These Companies

ResMed (NYSE:RMD) Stock Rating Cut to Hold at Canaccord Genuity Group
November 2 at 8:05 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-resmed-nyse-rmd-stock-rating-cut-to-hold-at-canaccord-genuity-group-2026-11-02/
ResMed consensus price target increased by 22.60% to MX$5,488.00
November 2 at 6:06 AM  |  msn.comhttps://www.msn.com/en-us/news/other/resmed-consensus-price-target-increased-by-2260-to-mx-548800/ar-AA2gy2rn
ResMed Inc. - Depositary receipt price target increased by 14.57% to $41.75
November 2 at 6:06 AM  |  msn.comhttps://www.msn.com/en-us/news/other/resmed-inc-depositary-receipt-price-target-increased-by-1457-to-4175/ar-AA2gyqkZ
ResMed: 3 Key Takeaways for Long-Term Investors
November 2 at 4:13 AM  |  fool.comhttps://www.fool.com/earnings/takeaways/2026/11/02/resmed-3-key-takeaways-for-long-term-investors/
ResMed (NYSE:RMD) Price Target Raised to $277.00
November 2 at 2:45 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31173159
ResMed (NYSE:RMD) Price Target Raised to $270.00
November 2 at 2:45 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31173158
ResMed (NYSE:RMD) Price Target Raised to $250.00
November 2 at 2:45 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31173153
RMD Q3 deep dive: product innovation and supply chain execution drive results amid evolving landscape
November 1 at 4:32 PM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/rmd-q3-deep-dive-product-230700542.html
ResMed (NYSE:RMD) Stock Price Breaks Below Fifty Day Moving Average - What's Next?
October 31 at 6:59 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-resmed-nyse-rmd-stock-price-breaks-below-fifty-day-moving-average-whats-next-2026-10-31/
ResMed (RMD) Looks Fully Valued After Another Earnings Beat
October 30 at 8:23 PM  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/resmed-rmd-looks-fully-valued-191602154.html
ResMed (NYSE:RMD) Stock Price Expected to Rise, Citigroup Analyst Says
October 30 at 4:47 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-resmed-nyse-rmd-stock-price-expected-to-rise-citigroup-analyst-says-2026-10-30/
Wells Fargo Adjusts Price Target on ResMed to $250 From $215
October 30 at 3:23 PM  |  marketscreener.comM
ResMed earnings rise as annual outlook stays unchanged
October 30 at 3:23 PM  |  finchannel.comF
Resmed beats earnings expectations but sticks with prior guidance
October 30 at 3:23 PM  |  massdevice.comhttps://www.massdevice.com/resmed-beats-earnings-expectations-but-sticks-with-prior-guidance/
ResMed (RMD) Q1 2027 Earnings Call Transcript
October 30 at 3:23 PM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/resmed-rmd-q1-2027-earnings-150040847.html
ResMed (NYSE:RMD) Price Target Raised to $288.00
October 30 at 1:17 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-resmed-nyse-rmd-price-target-raised-to-28800-2026-10-30/
Wells Fargo & Company Issues Positive Forecast for ResMed (NYSE:RMD) Stock Price
October 30 at 1:17 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-wells-fargo-company-issues-positive-forecast-for-resmed-nyse-rmd-stock-price-2026-10-30/
ResMed (RMD) Reports Q1 Earnings: What Key Metrics Have to Say
October 30 at 10:31 AM  |  zacks.comhttps://www.zacks.com/stock/news/3019551/resmed-rmd-reports-q1-earnings-what-key-metrics-have-to-say?cid=cs-stocknewsapi-ft-fundamental_analysis|nfm-3019551
ResMed (NYSE:RMD) Stock Gets Price Target Bump from KeyCorp
October 30 at 8:53 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-resmed-nyse-rmd-stock-gets-price-target-bump-from-keycorp-2026-10-30/
ResMed Inc. (NYSE:RMD) Shares Set to Pay Quarterly Dividend of $0.66
October 30 at 8:49 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/dividend-resmed-inc-nyse-rmd-shares-set-to-pay-quarterly-dividend-of-066-2026-10-30/
RMD Stock Up on Q1 Earnings and Revenue Beat, Gross Margin Climbs
October 30 at 8:30 AM  |  zacks.comhttps://www.zacks.com/stock/news/3019354/rmd-stock-up-on-q1-earnings-and-revenue-beat-gross-margin-climbs?cid=cs-stocknewsapi-ft-analyst_blog|earnings_article-3019354

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Illuminated Nike swoosh logo on a wall above a display pedestal with sneakers in a retail store.
Could Nike’s Brutal Sell-Off Finally Be Running Out of Steam?
By Thomas Hughes | October 4, 2026
Kalshi and Polymarket logos beside a smartphone showing a prediction market on the Chiefs winning the Super Bowl, with a football in the background.
Want Private-Market Access to Kalshi and Polymarket? Try This ETF
By Jessica Mitacek | October 8, 2026
Salesforce cloud logo in a futuristic tech setting, highlighting CRM enterprise software and AI platform growth.
Salesforce Fuels AI Engine With $5.66B Braze Buyout
By Jeffrey Neal Johnson | October 21, 2026
Digital screen displays a red candlestick stock chart trending downward, illustrating a declining market against a city skyline.
3 Stocks Chopped in Half: Why These Drops May Be Structural, Not a Dip
By Dan Schmidt | October 11, 2026
A pie baked with one-dollar and five-dollar bills inside, with one slice cut out, symbolizing profit sharing.
3 Stocks Delivering Bigger Dividends Despite Market Uncertainty
By Leo Miller | October 17, 2026
DexCom stock logo

DexCom NASDAQ:DXCM

$84.24 +1.95 (+2.37%)
As of 01:23 PM Eastern
This is a fair market value price provided by Massive. Learn more.

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.

GE HealthCare Technologies stock logo

GE HealthCare Technologies NASDAQ:GEHC

$79.86 +3.29 (+4.30%)
As of 01:23 PM Eastern
This is a fair market value price provided by Massive. Learn more.

GE HealthCare Technologies Inc. engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics. The Imaging segment offers molecular imaging, computed tomography (CT) scanning, magnetic resonance (MR) imaging, image-guided therapy, X-ray systems, and women's health products. The Ultrasound segment provides medical devices and solutions for screening, diagnosis, treatment, and monitoring of certain diseases in clinical areas, such as radiology and primary care, women's health, cardiovascular, and point of care and handheld ultrasound solutions, as well as surgical visualization and guidance products. The Patient Care Solutions segment provides medical devices, consumables, services, and digital solutions. Its portfolio includes patient monitoring solutions, anesthesia delivery and respiratory care products, electrocardiogram solutions, maternal infant care products, and consumables and services. The Pharmaceutical Diagnostics supplies diagnostic agents, including CT, angiography and X-ray, MR, single-photon emission computed tomography, positron emission tomography, and ultrasound to the radiology and nuclear medicine industry. The segment also provides contrast media pharmaceuticals that are administered to a patient prior to certain diagnostic scans to increase the visibility of tissues or structures during imaging exams; and molecular imaging agents or radiopharmaceuticals, which are molecular tracers labeled with radioisotopes. It has an AI collaboration with Mass General Brigham. The company was formerly known as GE Healthcare Holding LLC and changed its name to GE HealthCare Technologies Inc. in December 2022. The company was incorporated in 2022 and is headquartered in Chicago, Illinois.

Insulet stock logo

Insulet NASDAQ:PODD

$152.26 +2.58 (+1.72%)
As of 01:23 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, Australia, and internationally. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.

ResMed stock logo

ResMed NYSE:RMD

$231.44 +1.50 (+0.65%)
As of 01:23 PM Eastern
This is a fair market value price provided by Massive. Learn more.

ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; U-Sleep, a compliance monitoring solution that enables home medical equipment (HME) to streamline their sleep programs; connectivity module and propeller solutions; and Propeller portal. It offers out-of-hospital software solution, such as Brightree business management software and service solutions to providers of HME, pharmacy, home infusion, orthotics, and prosthetics services; MatrixCare care management and related ancillary solutions to senior living, skilled nursing, life plan communities, home health, home care, and hospice organizations, as well as related accountable care organizations; HEALTHCAREfirst that offers electronic health record, software, billing and coding services, and analytics for home health and hospice agencies; and MEDIFOX DAN's software solutions. The company markets its products to sleep clinics, home healthcare dealers, and hospitals through a network of distributors and direct sales force. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas